Compare MG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | ASMB |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.7M | 442.9M |
| IPO Year | 2008 | 2010 |
| Metric | MG | ASMB |
|---|---|---|
| Price | $18.68 | $26.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 152.7K | ★ 190.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $700,970,000.00 | N/A |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $3.59 | $638.39 |
| P/E Ratio | $268.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.74 | $16.90 |
| 52 Week High | $19.64 | $39.71 |
| Indicator | MG | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 54.65 |
| Support Level | $13.75 | $26.40 |
| Resistance Level | $19.39 | $31.21 |
| Average True Range (ATR) | 0.64 | 1.63 |
| MACD | 0.02 | 0.44 |
| Stochastic Oscillator | 49.01 | 74.98 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.